Literature DB >> 2625033

Hemoglobin A1 in cirrhosis of the liver.

Y Nomura1, K Nanjo, M Miyano, H Kikuoka, S Kuriyama, M Maeda, K Miyamura.   

Abstract

Patients with cirrhosis of the liver (LC group, n = 12) frequently have glucose intolerance secondary to hepatic dysfunction. We compared HbA1 levels and other measures of blood sugar control in the LC group with those in healthy controls (N group, n = 43), patients with diabetes mellitus (DM group, n = 36), or patients with chronic hepatitis without evidence of cirrhosis (CH group, n = 12). HbA1 levels and the mean values of fasting plasma glucose for the past month (FPG) were as follows: LC group 6.40 +/- 0.36 (mean +/- SEM)% and 130 +/- 20 mg/dl, DM group 10.29 +/- 0.45% and 172 +/- 11 mg/dl, CH group 10.70 +/- 0.86% and 176 +/- 21 mg/dl, N group 6.52 +/- 0.11% and 83 +/- 1 mg/dl, respectively. HbA1 in the LC group was similar to that in the N group, although FPG in the former was higher (p less than 0.05). All groups showed statistically significant positive correlations between HbA1 levels and (a) FPG, (b) the daily profile of plasma glucose values, (c) the total or peak plasma glucose values during a 50 g-OGTT. The regression line in the LC group, however, was statistically different from that in DM or CH group. Thus, HbA1 in the LC group is lower than that in DM or CH in spite of equivalent glucose intolerance. Therefore, we suggest caution in the interpretation of HbA1 levels in hepatic cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2625033

Source DB:  PubMed          Journal:  Diabetes Res        ISSN: 0265-5985


  7 in total

1.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

2.  Intensified blood glucose treatment in diabetic patients undergoing a liver transplant: impact on graft evolution at 3 months and at 5 years.

Authors:  A Ramos-Prol; D Hervás-Marín; B Rodríguez-Medina; M Rubio-Almanza; M Berenguer; Á Moya-Herraiz; J F Merino-Torres
Journal:  J Endocrinol Invest       Date:  2017-12-30       Impact factor: 4.256

3.  Determination of glycated hemoglobin in patients with advanced liver disease.

Authors:  Theresa Lahousen; Karin Hegenbarth; Rottraut Ille; Rainer-W Lipp; Robert Krause; Randie-R Little; Wolfgang-J Schnedl
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

4.  Utility and Limitations of Glycated Hemoglobin (HbA1c) in Patients with Liver Cirrhosis as Compared with Oral Glucose Tolerance Test for Diagnosis of Diabetes.

Authors:  Tejasav Sehrawat; Anuraag Jindal; Paaras Kohli; Amit Thour; Jasbinder Kaur; Atul Sachdev; Yashdeep Gupta
Journal:  Diabetes Ther       Date:  2018-01-05       Impact factor: 2.945

5.  Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin.

Authors:  Thanida Tangjarusritaratorn; Watip Tangjittipokin; Tada Kunavisarut
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-09       Impact factor: 3.168

6.  Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring.

Authors:  Fumi Honda; Akira Hiramatsu; Hideyuki Hyogo; Hiroshi Aikata; Kana Daijo; Yuji Teraoka; Yuki Inagaki; Kei Morio; Tomoki Kobayashi; Takashi Nakahara; Yuko Nagaoki; Tomokazu Kawaoka; Masayasu Yoneda; Masataka Tsuge; Michio Imamura; Yoshiiku Kawakami; Hidenori Ochi; Kazuaki Chayama
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

7.  Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites.

Authors:  Tammo L Tergast; Hans Laser; Svetlana Gerbel; Michael P Manns; Markus Cornberg; Benjamin Maasoumy
Journal:  Clin Transl Gastroenterol       Date:  2018-09-24       Impact factor: 4.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.